Viveve Medical Inc (VIVE) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Viveve Medical Inc (NASDAQ:VIVE) have earned an average rating of “Buy” from the eight research firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $10.00.

Several equities research analysts recently commented on the stock. Mizuho reiterated a “buy” rating and issued a $10.00 price objective on shares of Viveve Medical in a research report on Friday. Northland Securities assumed coverage on shares of Viveve Medical in a research report on Friday. They issued an “outperform” rating and a $8.00 price objective on the stock. Ladenburg Thalmann Financial Services reiterated a “buy” rating on shares of Viveve Medical in a research report on Thursday. Cowen set a $11.00 price objective on shares of Viveve Medical and gave the stock a “buy” rating in a research report on Monday, October 23rd. Finally, ValuEngine lowered shares of Viveve Medical from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st.

Shares of Viveve Medical (NASDAQ:VIVE) traded down $0.01 during midday trading on Friday, hitting $4.96. 123,658 shares of the company’s stock traded hands, compared to its average volume of 134,600. The stock has a market cap of $96.36, a price-to-earnings ratio of -2.31 and a beta of -0.67. Viveve Medical has a 52 week low of $3.75 and a 52 week high of $11.16. The company has a quick ratio of 3.63, a current ratio of 3.89 and a debt-to-equity ratio of 2.72.

Viveve Medical (NASDAQ:VIVE) last released its quarterly earnings data on Wednesday, November 8th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.08). Viveve Medical had a negative return on equity of 275.77% and a negative net margin of 257.58%. The business had revenue of $4.07 million during the quarter, compared to analysts’ expectations of $4.10 million. During the same quarter in the prior year, the firm earned ($0.46) earnings per share. Viveve Medical’s quarterly revenue was up 120.1% on a year-over-year basis. equities research analysts forecast that Viveve Medical will post -2.04 earnings per share for the current year.

Several institutional investors have recently added to or reduced their stakes in the stock. HighTower Advisors LLC lifted its holdings in Viveve Medical by 33.2% in the 2nd quarter. HighTower Advisors LLC now owns 1,723,751 shares of the company’s stock valued at $12,379,000 after purchasing an additional 430,033 shares in the last quarter. RTW Investments LP lifted its holdings in Viveve Medical by 18.8% in the 3rd quarter. RTW Investments LP now owns 1,473,028 shares of the company’s stock valued at $7,719,000 after purchasing an additional 233,585 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Viveve Medical by 135.4% in the 2nd quarter. Vanguard Group Inc. now owns 450,142 shares of the company’s stock valued at $3,232,000 after purchasing an additional 258,912 shares in the last quarter. Manatuck Hill Partners LLC lifted its holdings in Viveve Medical by 128.6% in the 2nd quarter. Manatuck Hill Partners LLC now owns 400,000 shares of the company’s stock valued at $2,872,000 after purchasing an additional 225,000 shares in the last quarter. Finally, ING Groep NV lifted its holdings in Viveve Medical by 93.7% in the 3rd quarter. ING Groep NV now owns 325,000 shares of the company’s stock valued at $1,703,000 after purchasing an additional 157,200 shares in the last quarter. Institutional investors and hedge funds own 66.90% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Viveve Medical Inc (VIVE) Receives Consensus Recommendation of “Buy” from Analysts” was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/05/viveve-medical-inc-vive-receives-consensus-recommendation-of-buy-from-analysts-2.html.

Viveve Medical Company Profile

Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.

Analyst Recommendations for Viveve Medical (NASDAQ:VIVE)

Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply